FDA Scrutiny of Peptides and Biohacking Regulation Intensifies
Key Questions
Which peptides is the FDA advisory panel reviewing?
The panel will examine BPC-157 and MOTS-c amid safety concerns including heavy metal contamination and insufficient evidence. RFK Jr. has advocated for deregulation of several peptides.
What evidence gaps exist for NAD+ IV drips and NMN?
NAD+ IV drips lack supporting human trial data for claimed benefits, while NMN has re-emerged in discussions despite prior regulatory scrutiny. EMA has issued new guidelines on synthetic peptides.
How is the regulatory landscape changing for biohacking compounds?
FDA scientists cite safety risks and evidence shortfalls even as deregulation pushes occur, with expanded evidence reviews from sources like Evipedia and new EMA synthetic peptide guidelines tightening oversight.
What is Epithalon peptide primarily used for?
Epithalon is discussed in longevity contexts for potential anti-aging effects, though evidence remains limited according to board-certified reviews of peptide therapies.
Why are anti-aging peptide claims under increased scrutiny?
Insufficient clinical evidence and contamination risks have prompted FDA reviews, contrasting with RFK Jr.'s deregulation stance and highlighting the need for stronger human trial data.
FDA advisory panel to review peptides BPC-157 and MOTS-c, with RFK Jr. pushing deregulation but FDA scientists citing insufficient evidence and safety concerns (heavy metals, contamination). NAD+ IV drips lack human trial evidence, while NMN re-emerges. Now, a critical preclinical study warns that NAD+ boosters (NMN, NR, NAM) may help pancreatic cancer cells survive chemotherapy, challenging safety assumptions for users undergoing cancer treatment. EMA issued new synthetic peptide guideline. Evidence-based resources emerging: Evipedia, neurologist's graded review, critical analysis of Epithalon. The regulatory landscape for biohacking compounds is shifting, with growing demand for evidence.